Cyclic Guanosine Monophosphate and Risk of Incident Heart Failure and Other Cardiovascular Events: the ARIC Study

BACKGROUND: Cyclic guanosine monophosphate (cGMP) is a second messenger regulated through natriuretic peptide and nitric oxide pathways. Stimulation of cGMP signaling is a potential therapeutic strategy for heart failure with preserved ejection fraction (HFpEF) and atherosclerotic cardiovascular dis...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Am Heart Assoc
Hauptverfasser: Zhao, Di, Guallar, Eliseo, Vaidya, Dhananjay, Ndumele, Chiadi E., Ouyang, Pamela, Post, Wendy S., Lima, Joao A., Ying, Wendy, Kass, David A., Hoogeveen, Ron C., Shah, Sanjiv J., Subramanya, Vinita, Michos, Erin D.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2020
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7033823/
https://ncbi.nlm.nih.gov/pubmed/31928156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.119.013966
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge